American Trust Biomarin Pharmaceutical Inc Transaction History

American Trust

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $26,524 - $30,691	-306 Reduced 11.66%	2,318 $200,000
Q1 2023 May 22, 2023	SELL	$87.74 - $117.27 $7,282 - $9,733	-83 Reduced 3.07%	2,624 $255,000
Q4 2022 Feb 16, 2023	SELL	$80.93 - $108.63 $4,127 - $5,540	-51 Reduced 1.85%	2,707 $280,000
Q3 2022 Dec 02, 2022	SELL	$82.16 - $96.94 $4,929 - $5,816	-60 Reduced 2.13%	2,758 $229,000
Q2 2022 Oct 03, 2022	BUY	$71.48 - $86.85 $5,003 - $6,079	70 Added 2.55%	2,818 $234,000
Q1 2022 Jun 08, 2022	SELL	$74.28 - $92.69 $11,290 - $14,088	-152 Reduced 5.24%	2,748 $212,000
Q4 2021 Mar 17, 2022	BUY	$71.72 - $91.47 $207,988 - $265,263	2,900 New	2,900 $256,000

638

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of American Trust, based on Form 13F filings with the SEC.

Stay updated on American Trust with notifications on news.